Back to Screener

Healthcare

Abbott Laboratories(ABT)

Data coverage status · 6 need attention

Quote through 2026-08-05T13:30:00Z · Stale

Quote synced 2026-08-05T23:25:48.499015Z

Daily bars through 2026-08-03 · Stale

Daily bars synced 2026-08-04T15:35:19.331132Z

Fundamentals through 2026-05-04 · Current

Fundamentals synced 2026-08-05T22:39:51.787625Z

Forecasts: Stale

Forecasts synced 2026-05-05T11:57:48.711655Z

Ownership: Missing

Ownership synced 2026-08-05T22:39:51.787625Z

Short interest: Missing

Short interest synced 2026-08-05T22:39:51.787625Z

News through 2026-05-21T02:30:00Z · Stale

News synced 2026-05-21T08:13:40.628796Z

Company profile: Delayed

Company profile synced 2026-05-06T21:57:49.68488Z

Regular-session price

Offline

$105.71

+0.24% regular session

1Y Change

-19.06%

Window

Aug 5, 2025 → Aug 4, 2026

Market Cap
$152.55B
P/E
24.4
Trailing
52W Range
$81.97 - $137.49
Volume
8.73M
0.7x RVOL

Investment Snapshot

Valuation, growth, profitability, catalysts, and benchmark context.

Quote + TTM fundamentalsForecast

1D

+0.2%

1M

+10.6%

6M

-2.2%

YTD

-14.8%

1Y

-19.1%

Coverage: 250 bars · Aug 5, 2025 → Aug 4, 2026

Benchmark Edge

ABT vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

ABT trails SPY

ABT is 41.89 pts behind over the shared 1Y window.

ABT had 30.44 pts deeper max drawdown than SPY.

ABT beat SPY in 0 of 2 calendar years shown and trailed in 2.

ABT

-19.06%

Normalized return

SPY

+22.83%

S&P 500

Excess Return

-41.89 pts

Relative to SPY

ABT Max Drawdown

-39.57%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

ABTSPY

Calendar-Year Returns

Uses the longest available daily history for ABT and SPY.

YearABTSPYExcessLeader
2026-14.82%+12.67%-27.50 ptsSPY
2025-3.76%+9.40%-13.16 ptsSPY

EPS Consensus

1.89

Range 1.86 -> 1.91

No analyst count

vs prior: +7.9%

Revenue Outlook

$15.6B

Range $15.4B -> $15.7B

No analyst count

vs prior: +2.9%

Price Target

--

-- -> --

No analyst count

Recommendations

--

No recommendation feed

No date

Consensus Spread

EPS spread2.6%
Revenue spread2.0%

Lower spread suggests tighter agreement across covering analysts.

Next Earnings

Oct 16, 2026

EPS --

Revenue --

No analyst count

EPS Revisions

No revision signal

No recent EPS revision rows

0 revision rows

Trend

EPS trend

Consensus average across visible periods

1.89
Latest visible period
Q3 2027Q4 2028
6 visible pointstrend: +7.9%

Trend

Revenue trend

Average analyst revenue estimate

$15.6B
Latest visible period
Q3 2027Q4 2028
6 visible pointstrend: +2.9%

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from the configured analyst feed.

Q4 2028
Ends Dec 31, 2028
quarter
Revenue
$15.6B
$15.4B to $15.7B
EPS
1.89
1.86 to 1.91
No analyst count
EPS: No analyst count
May 5, 11:57 AM UTC
stable/analyst-estimates
Q3 2028
Ends Sep 30, 2028
quarter
Revenue
$15.1B
$15.0B to $15.3B
EPS
1.75
1.73 to 1.77
No analyst count
EPS: No analyst count
May 5, 11:57 AM UTC
stable/analyst-estimates
Q2 2028
Ends Jun 30, 2028
quarter
Revenue
$14.5B
$14.3B to $14.6B
EPS
1.62
1.60 to 1.64
No analyst count
EPS: No analyst count
May 5, 11:57 AM UTC
stable/analyst-estimates
Q1 2028
Ends Mar 31, 2028
quarter
Revenue
$13.8B
$13.6B to $13.9B
EPS
1.49
1.47 to 1.51
No analyst count
EPS: No analyst count
May 5, 11:57 AM UTC
stable/analyst-estimates
Q4 2027
Ends Dec 31, 2027
quarter
Revenue
$14.5B
$14.4B to $14.7B
EPS
1.74
1.71 to 1.76
No analyst count
EPS: No analyst count
May 5, 11:57 AM UTC
stable/analyst-estimates
Q3 2027
Ends Sep 30, 2027
quarter
Revenue
$14.1B
$14.0B to $14.2B
EPS
1.58
1.56 to 1.60
No analyst count
EPS: No analyst count
May 5, 11:57 AM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.